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The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor
receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has
notably evolved during the last decades, the invariable appearance of endocrine resistance, either primary or
secondary, remains an important issue in this type of tumor. The improvement of our understanding of the cancer
genome has identified some promising targets that might be responsible or linked to endocrine resistance,
including alterations affecting main signaling pathways like PI3K/Akt/mTOR and CCND1/CDK4-6 as well as the
identification of new ESR1 somatic mutations, leading to an array of new targeted therapies that might circumvent
or prevent endocrine resistance. In this review, we have summarized the main targeted therapies that are currently
being tested in ER+ breast cancer, the rationale behind them, and the new agents and combinational treatments
to come.
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Endocrine therapy represents a major treatment in all set-
tings of the disease for breast cancers expressing estrogen
receptor (ER)-α, which accounts for around 70 % of tu-
mors [1, 2]. During the last two decades, third-generation
aromatase inhibitors (AIs), such as anastrozole, letrozole,
and exemestane, have become the standard endocrine
treatment in postmenopausal women both in advanced
and early disease, contributing to an improvement in me-
dian survival from 28 to 45 months between the late
1980s and late 1990s [3]. Despite the efficacy of these
compounds, response rates for first-line metastatic pa-
tients have been described as up to 40 %, with all initial re-
sponders eventually developing resistance over time [4].
After progression on an AI, it might still be indicated to
pursue with another endocrine agent like fulvestrant, un-
less there is significant visceral burden and rapid tempo of
disease [5]. Other possibilities include treatment with a se-
lective estrogen receptor modulator like tamoxifen or even
hormone additive therapies, such as the use of progestins* Correspondence: fabrice.andre@gustaveroussy.fr
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unless otherwise stated.(medroxyprogesterone acetate) [6] and estrogen (ethinyl
estradiol) [7, 8].
Due to its clinical significance, extensive research has
been made in order to determine the potential mecha-
nisms of endocrine resistance. Initial studies had identi-
fied the loss of ER expression as responsible for primary
resistance, as well as polymorphisms of CYP2D6 and
CYP19A1 as being responsible for the lack of benefit
from tamoxifen and aromatase inhibitors, respectively
[9–12], although further studies have not been able to
confirm these findings [12, 13]. For both primary as well
as secondary resistance, one of the main responsible
mechanisms is thought to be the interaction between ER
and growth factor receptor signaling via either the
phosphatidylinositol-3-kinase (PI3K)/protein kinase B
(Akt)/mammalian target of rapamycin (mTOR) pathway,
or the mitogen-activated protein kinase (MAPK) path-
way which promotes ER phosphorylation (therefore acti-
vation) via a non-classical genomic pathway [14] (Fig. 1).
More recently, high-throughput technologies studies in
ER-positive metastatic breast cancer samples have iden-
tified a large number of molecular aberrations in poten-
tial driver genes such as PIK3CA mutations, FGFR1
and CCND1 amplifications (11 %), and ESR1 mutations
(4 %) [12, 15–19], some of them previously linked toen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Cross-talk between ER signaling and growth factor signaling pathways described as linked to resistance to endocrine therapy. Classical ER
signaling needs to bind to estrogens and HSP90 chaperone protein before binding to transcription start site of target genes such as cyclin D.
This transcription activity is partly mediated by histone deacetylation by HDAC6. CyclinD activates E2F transcription via Rb phosphorylation and
promotes G1-S transition into the cell cycle for cell proliferation. Suppression of classical ER signaling by endocrine therapy might promote activation of
the tyrosine kinase receptor signaling pathways PI3K/Akt/mTOR and RAS-RAF-MAPK via its effectors S6K1 and 4EBP1 to promote ligand-independent
activation of ER. Numbers shown in this figure correspond to the function sites of the target agents described in the manuscript. ①mTOR
inhibitor: inhibition of mTORC1 down-regulated S6K1 and 4EBP1. In mTOR inhibitor resistance, feedback signaling seems to be activated indicated by
white arrow.②,③PI3K inhibitors and Akt inhibitors.④CDK4/6 inhibitors.⑤FGFR inhibitors.⑥HDAC6 inhibitors.⑦Specific inhibitory agents for mutant
ER (ex. HSP90 inhibitors). This figure was exclusively drawn for this article
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interest in the cell cycle regulation pathway cyclin D1/
cyclin-dependent kinases [20], has resulted in the ap-
pearance of several therapies targeting these pathways
in order to circumvent or delay the development of
endocrine resistance.
In this review, we summarize the rationale and the key
clinical data obtained to date with targeting therapies for
ER+/human epidermal growth factor receptor (HER)2-
advanced breast cancer. This review is complementary to
the one reported in the same journal by Migliaccio et al.
[21], since it will discuss mostly new targeted therapies
and mechanisms of resistance.
mTOR inhibitors
The PI3K (phosphatidylinositol 3-kinase), Akt/PKB (pro-
tein kinase B), and mTOR (mammalian target of rapamy-
cin) pathway is an intracellular pathway which mediates
gene activation, cell cycle, survival, metabolism motility,
and genomic instability [22]. The pathway also contributes
to cancer-promoting aspects of the tumor environment,
such as angiogenesis [23].
The PI3K pathway is the most frequently altered path-
way in breast cancer: the PIK3CA gene (encoding the
catalytic isoform p110α) is the second most frequently
mutated oncogene, and PTEN (encoding the phosphat-
ase and tensin homolog) is among the most mutated
tumor suppressor genes [24, 25]. In addition, many other
molecular alterations within different components of the
pathway, including PIK3CA amplifications, AKT1 muta-
tions, and PTEN loss, have been observed in ER+ breast
cancer [16, 25]. Moreover, the PI3K/Akt/mTOR pathway
has been described as potentially intervening in secondary
endocrine resistance in ER+ breast cancer [16, 26, 27]. In
preclinical models, long-term estrogen-deprived breast
cancer cells show an up-regulation of the PI3K pathway
leading to a ligand-independent activation of ER by
its phosphorylation through the mTOR complex 1
(mTORC1)/S6K1 axis [26, 28]. A series of first-
generation mTOR inhibitors have been developed
including everolimus (Afinitor, Novartis) [29] and tem-
sirolimus (Torisel, Wyeth) [30] as rapamycin derivatives
that inhibit mTOR through allosteric binding to
mTORC1. In preclinical models, the use of everolimus
in combination with aromatase inhibitors (AIs) results
in synergistic inhibition of proliferation and induction
of apoptosis [31]. In a randomized, phase II study com-
paring neoadjuvant everolimus plus letrozole with
letrozole alone in patients with newly diagnosed ER-
positive breast cancer, the response rate for the com-
bination was higher than that for letrozole alone [32].
Several phase II and III studies including an mTOR in-
hibitor have been completed in patients with advanced
hormone receptor (HR)+ breast cancer, and so far threemajor randomized trials have reported consistent data
in efficacy [33–35] (Table 1). The phase III trial BO-
LERO (Breast cancer trials of oral everolimus)-2 en-
rolled 724 patients who were randomized to receive
everolimus combined with exemestane (a steroidal AI)
versus exemestane plus placebo in postmenopausal pa-
tients with HR+ advanced breast cancer previously
treated with a non-steroidal AI (letrozole or anastro-
zole). At the time of the pre-planned analysis, median
progression-free survival (PFS) was significantly better
for the everolimus plus exemestane arm compared to
the control arm (6.9 versus 2.8 months, HR 0.43, 95 %
CI 0.35 to 0.54, P < 0.001 according to local assess-
ment) [34]. The results of this study led to the approval
by the FDA and EMA of everolimus in combination with
exemestane in postmenopausal patients with advanced
HR+ breast cancer previously exposed to letrozole or ana-
strozole. Final study results with median 18-month
follow-up show that median PFS remained significantly
longer with everolimus plus exemestane versus placebo
plus exemestane in the overall population [investigator re-
view: 7.8 versus 3.2 months, respectively; HR = 0.45 (95 %
CI 0.38 to 0.54); P < 0.0001; central review: 11.0 versus 4.1
months, respectively; HR = 0.38 (95 % CI 0.31 to 0.48);
P < 0.0001] [36]. Updated results have not found a signifi-
cant benefit for overall survival (OS) with the combination
arm, although a trend was observed, with a median OS of
31 months versus 27 months for everolimus versus the
placebo arm, respectively; (HR = 0.89; 95 % CI 0.73 to
1.10; P = 0.14) [37]. Similarly, the French phase II study
TAMRAD (tamoxifen plus everolimus) randomized endo-
crine therapy alone (in this case tamoxifen) versus tamoxi-
fen plus everolimus in patients again with metastatic ER+
breast cancer previously treated with endocrine therapy
[33]. In this trial including a total of 111 patients, clinical
benefit rate (CBR) at 6 months (the primary endpoint)
was clearly superior for the combination arm as compared
with tamoxifen alone (61 % versus 42 % for combined
therapy versus tamoxifen alone, respectively (exploratory
P = 0.045). Time to progression (TTP) was also favorable
in the combination arm (8.6 versus 4.5 months; HR 0.54,
95 % CI 0.36 to 0.81, P = 0.0021). There was also a benefit
in OS for the mTOR-inhibitor arm (not reached versus
32.9 months, HR 0.45, 95 % CI 0.24 to 0.81, P = 0.007)
[33]. Interestingly, the HORIZON trial, a phase III study
in postmenopausal women with HR+ breast cancer that
randomized 1,112 patients to receive the mTOR inhibitor
temsirolimus in combination with letrozole versus letro-
zole plus placebo as first-line endocrine treatment, was
closed prematurely following an intermediate analysis due
to futility [35]. The analysis showed no difference in PFS,
the primary endpoint, between the two arms (median PFS
of 9 months; HR 0.90, 95 % CI 0.76 to 1.07, P = 0.25).
There are several ongoing major randomized trials with
Table 1 Main clinical trials with targeted agents for ER+/HER2- advanced/metastatic breast cancer: mTOR inhibitors, PI3K inhibitors, and Akt inhibitors
Target Function Agent Trial Phase Design Results with significance/Study status
Line Arm CBR TTP Median PFS Median OS
mTOR mTOR inhibitor Evelorimus BOLERO-2
[17–19]





II First line LET + evelorimus vs. LET Ongoing
BOLERO-6
NCT01783444
II nsAI failure EXE + evelorimus vs. EXE vs.
capecitabine
Ongoing




Tensirolimus HORIZON [21] III First line LET + tensirolimus vs. LET Terminated n.s.
mTORC mTORC dual TORC1/2
inhibitor
MLN0128 NCT02049957 I/II MLN0128 + EXE vs. MLN0128
+ FUL
Ongoing
PI3K Pan-PI3 K inhibitor BKM120 BELLE-2
NCT01610284












III First line BKM120 vs. BKM120 + PTX Terminated n.s.
PI3K-α inhibitor BYL719 NCT02058381 II Premenopausal
patients
BYL719 + TAM + Gos vs.





XL147/XL765 NCT01082068 I/II nsAI failure XL147 + LET vs. XL765 + LET Completed
dual PI3K/mTOR inhibitor GDC0941/GDC0980 NCT01437566 II AI failure Fulvestrant + GDC0941 vs.
fulvestrant + GDC0980 vs.
fulvestrant






Akt Akt inhibitor AZD2014 MANTA
NCT02216786
II AI failure AZD2014 + FUL vs. everolimus




I/II Part B: PI3CA mut AZD5363 + wPTX vs. wPTX Ongoing
MK2206 NCT01277757 II PIK3CA mut AKT
mut PTEN loss/mut
Monotherapy Terminated
Abbreviations: mTOR: mammalian target of rapamycin, AI: aromatase inhibitor, nsAI: non-steroidal AI, EXE: exemestane, LET: letrozole, TAM: tamoxifen, TORC: mTOR complex, FUL: fulvestrant, PI3K: phosphatidylinositol-
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ing BOLERO-4, which will evaluate the benefit from the
combination of everolimus and letrozole as first-line treat-
ment (NCT01698918) and might be able to determine if
the lack of benefit observed with temsirolimus in the
HORIZON study was related to patient population, as
preclinical studies have observed that the PI3K/Akt/
mTOR pathway is mostly activated after previous endo-
crine therapy exposure. Finally, the BOLERO-6 trial is an
ongoing three-arm phase II randomized study comparing
everolimus plus exemestane, exemestane alone, and cape-
citabine (NCT01783444) in postmenopausal patients with
HR+ breast cancer already exposed to endocrine therapy.
Many efforts have been performed in order to identify
potential biomarkers of benefit from mTOR inhibition
in patients with breast cancer. Immunohistochemistry
(IHC) studies conducted on 55 formalin-fixed paraffin-
embedded primary samples from the TAMRAD trial
suggested that everolimus is more effective for tumors
presenting with high levels of p4EBP1 (a downstream ef-
fector of the mTOR pathway), suggesting that baseline
mTOR activation might be associated with sensitivity to
mTOR inhibition [38]. In parallel, next-generation se-
quencing studies performed in 309 samples from the
BOLERO-2 trial found that the presence of more than
one molecular alteration (from four key pathways in-
cluding FGFR1/2 amplification, PIK3CA mutation,
PTEN loss, or CCDN1 amplification) was associated
with a lack of benefit from everolimus treatment (HR =
0.78; 95 % CI 0.39-1.54) [17]. These findings suggest that
primary resistance to mTOR inhibition might depend on
the coexistence of mutations or amplifications in other
pathways; therefore, combination therapy with other tar-
get agents should be considered for this population.
Interestingly, the presence of a PIK3CA mutation was
not predictive of benefit from everolimus treatment.
PI3K inhibitor/Akt inhibitor
As mentioned before, PI3K pathway alterations occur in
about 70 % of breast cancers and include mutations and/
or amplifications of the genes encoding the PI3K catalytic
subunits, p110α (PIK3CA) and p110β (PIK3CB), the PI3K
regulatory subunit p85α (PIK3R1), and the PI3K effectors
AKT1, AKT2, and PDK1. The loss of lipid phosphatases
such as PTEN can also activate the pathway [17, 39–42].
Preclinically, activation of RTK signaling has been seen to
induce transcription of growth-related genes and cause
decreases in ER levels and activity, leading to an inferior
response to endocrine therapy [43]. Cotargeting this path-
way with ER and PI3K inhibitors therefore appears to be a
promising therapeutic opportunity for patients with ER+
breast cancer.
The development of PI3K inhibitors is rapidly evolving
with newer and more potent compounds enteringclinical trials including pan-PI3K inhibitors targeting all
isoforms of PI3K, as well as the isoform-specific inhibi-
tors, like inhibitors of the PI3K catalytic subunit p110α,
which offer the potential of achieving greater selective
target blockade while minimizing off-target effects due
to inhibition of other isoforms. Some of the pan-PI3K
inhibitors include XL147 [44] and GDC-0941 [45], al-
though the most advanced in clinical research in HR-
positive breast cancer is the pan-PI3K inhibitor BKM120
(buparlisib) [46] (Table 1). So far, single-agent clinical
trials with pan-PI3K inhibitors have shown modest effect
[44, 45, 47]. BKM120 has been evaluated for safety, tol-
erability, and preliminary activity in combination with
letrozole in ER+/HER2- metastatic breast cancer pa-
tients refractory to endocrine therapy [48]. The CBR, its
primary objective, was of 31 out of 51 patients. Buparli-
sib's maximum-tolerated dose (MTD) was 100 mg/d.
Common drug-related adverse events included ≤ grade 2
hyperglycemia, nausea, fatigue, transaminitis, and mood
disorders. Buparlisib is currently being tested in two
phase III clinical trials in combination with fulvestrant
for patients previously treated with an AI (BELLE-2,
NCT01610284) and after resistance of mTOR inhibitor
(BELLE-3, NCT01633060). Of note, another phase II/III
trial evaluating the benefit of paclitaxel in combination
with BKM120 or placebo (BELLE-4, NCT01572727) in
first-line advanced HER2-negative breast cancer was re-
cently terminated after an interim analysis due to futility.
Another phase II trial of GDC-0941 in combination with
fulvestrant (NCT01437566), both in HR+ postmeno-
pausal breast cancer patients, was updated with a result
of no PFS significance in the combination group (HR =
0.74; 95 % CI 0.51-1.05), otherwise effective in the ER
and PR positive subgroup (HR = 0.44; 95 % CI 0.28-
0.69). The combination group showed no correlation in
the subgroup with PIK3CA mutation, but the patients
with PIK3CA mutation showed an accurately higher
objective response rate (15.8 % versus 3.1 %). Other clin-
ical trials, including the phase II study of XL147 in com-
bination with letrozole (NCT01082068), are currently
ongoing.
Preliminary reports about BYL719, a PI3K-α inhibitor,
have shown promising activity in patients with heavily
pretreated PIK3CA mutant breast cancer in a phase I
study. Out of the 17 patients treated, 8 (47 %) presented
a tumor shrinkage of >20 % [49]. BYL719 is currently
being tested in several phase I clinical trials in different
types of combinations including with letrozole in post-
menopausal patients harboring advanced breast cancer
(NCT01791478), with either letrozole or exemestane for
the same population (NCT01870505), or in endocrine-
sensitive premenopausal HR+ cancer with combined endo-
crine therapy of tamoxifen and goserelin (NCT02058381).
Whether selective PIK3CA isoform inhibitors may be
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which patient populations may benefit the most from their
use, are questions yet to be addressed.
In addition, the presence of a negative feedback loop
in the PI3K/Akt/mTOR pathway has been demonstrated,
in which activation of mTORC1/S6K1 inhibits growth
factor signaling to PI3K, exerting negative feedback to
restrict insulin and IGF-1 signaling. Loss of this negative
feedback mechanism has been shown to occur in cells
and tumors exposed to mTOR inhibitors, preferentially
those that inhibit mTORC1, which leads to mTORC2
assembly and an increase in phosphorylation of Akt
Ser473 [50]. mTOR inhibition also leads to an escape
signaling to RAS/RAF/MEK (MAPK signaling) [50, 51]
and to an up-regulation of platelet-derived growth factor
receptor (PDGFR) signaling [51, 52]. Thus, inhibition
upstream to mTOR in the PI3K-Akt pathway might be
expected to enhance mTOR inhibition and to exert an
anti-tumor effect [17, 39–46, 48, 49, 53].
In order to compensate this Akt activation by this
feedback loop caused by mTORC1 inactivation, several
different approaches are currently being studied. The
first one includes the dual blockade of PI3K and mTOR
by the combination of a PI3K inhibitor and an mTOR
inhibitor as is currently being tested in a phase II trial of
BYL719 in combination with everolimus and exemestane
(NCT02077933). Several dual PI3K/mTOR inhibitors
are also currently being investigated in phase II studies
in different types of tumors including HR+ advanced
breast cancer. A phase II randomized trial testing GDC-
0941 in combination with fulvestrant (NCT01437566) in
HR+ postmenopausal breast cancer patients did not re-
port a significant benefit on PFS (HR = 0.74; 95 % CI
0.51-1.05) [54]. PIK3CA mutations were not predictive
for the efficacy of GDC-0941. Another phase II trial is
ongoing with XL765 in combination with letrozole
(NCT01082068). Another approach is the use of
mTORC1/mTORC2 complex inhibitors like the four-
arm phase II study with AZD2014 in two different
schedules (continuous or intermittent) in association
with fulvestrant versus fulvestrant + everolimus versus
fulvestrant alone as the control arm (NCT02216786).
Of note, several Akt inhibitors are currently being
tested in clinical trials to determine their potential bene-
fit, some of them including patients with advanced
breast cancer (Table 1), although the trials are still at
early stages.
CDK inhibitor
The cyclin D1 and cyclin-dependent kinase 4 and 6
(CDK4/6) complex pathway is involved in cell cycle regu-
lation and several downstream signals. During cell cycle
progression, the cyclin D1-CDK4/6 complex mediates the
phosphorylation and inactivation of the retinoblastomaprotein (pRb), allowing for cells to progress from the G1
phase to the S phase [55]. In ER-positive breast cancer, the
presence of cyclin D1 amplification has been observed,
which causes cell cycle deregulation and results in over-
proliferation of cancer cells [56]. Therefore, inhibition of
the cyclin D1-CDK4/6 complex and the role it might play
in restoring cell cycle control in breast cancer is a critical
area of study. Results from early in vitro and in vivo
studies have demonstrated that treatment with PD
0332991, a selective cyclin D kinase 4/6 inhibitor, pref-
erentially inhibits proliferation of luminal ER-positive
human breast cancer cell lines in vitro [57]. Three dif-
ferent oral small-molecule CDK4/6 inhibitors are cur-
rently being investigated: palbociclib (Ibrance, Pfizer),
abemaciclib (LY2835219, Lilly), and LEE011 (Novartis)
(Table 2).
The phase II clinical trial PALOMA-1/TRIO-18
(NCT00721409), testing the efficacy of letrozole with or
without palbociclib, was conducted as first-line treat-
ment in HR+ postmenopausal breast cancer patients.
Final results have showed a median PFS of 10.2 months
(95 % CI 5.7-12.6) for patients in the letrozole alone
group, compared with 20.2 months (95 % CI 13.8-27.5)
for those given palbociclib plus letrozole (HR = 0.488, 95
% CI 0.319 to 0.748; one-sided P = 0.0004) [58]. Notably,
the benefit of palbociclib was not outweighed by excess
toxic effects, with neutropenia (without an increase in
febrile neutropenia) being the most common grade 3-4
adverse event. Several other adverse events were seen in
more than 20 % of patients, with increases noted in the
palbociclib group, but most were mild or manageable.
These results have led to approval of palbociclib in early
2015 by the Food and Drug Administration (FDA) for
the treatment of postmenopausal women with ER-
positive, HER2-negative advanced breast cancer as initial
endocrine-based therapy for their metastatic disease.
Palbociclib is also currently being tested in different
phase III clinical trials in patients with HR+ postmeno-
pausal advanced breast cancer with different combinations
including palbociclib plus letrozole versus letrozole mono-
therapy in first-line therapy (PALOMA-2, NCT01740427),
palbociclib plus fulvestrant versus fulvestrant monother-
apy (PALOMA-3, NCT01942135), and palbociclib plus
exemestane versus capecitabine (PEARL, NCT02028507),
these latter two studies in patients with resistance to AI.
Another CDK4/6 inhibitor, LEE011, is currently being in-
vestigated in a phase III clinical trial in association with
fulvestrant in first-line HR-positive advanced breast
cancer (MONALEESA-2: NCT01958021) for postmen-
opausal patients, and in association with nsAI/TAM
plus goserelin for premenopausal breast cancer (MON-
ALEESA-7: NCT02278120). Similarly, abemaciclib is
currently being tested in a phase III clinical trial in
combination with non-steroidal aromatase inhibitors
Table 2 Main trials of targeted agents for ER+/HER2- advanced/metastatic breast cancer: CDK inhibitors, FGFR inhibitors, HDAC inhibitors, and combined therapy
Target Function Agent Trial Phase Design Results with significance/Study status
Population Arms CBR TTP Median
PFS
Median OS
CDK CDK4/6 inhibitor Palbociclib PALOMA-1 [28] II First line Palbociclib + LET vs. LET
PALOMA-2
NCT01740427
III HTfailure Palbociclib + FUL vs. FUL Ongoing
PALOMA-3
NCT01942135
III First line Palbociclib + LET vs. LET Ongoing
PEARL
NCT02028507
III AI failure Palbociclib + EXE vs. capecitabine Ongoing
LEE011 MONALEESA-2
NCT01958021





LEE011 + nsAI/TAM + gos vs.
nsAI/TAM + gos
NCT01709370 II AI failure Monotherapy Ongoing
LY2835219 Monarch3
NCT02246621
III First line LY2835219+nsAI vs. nsAI Ongoing




II 1 line HT failure Monotherapy Ongoing
Dovitinib NCT00958971 II With or without FGFR
amplification
Monotherapy 21.1 % vs.
12.0 %
NCT01528345 II HT failure Dovitinib + FUL vs. FUL Ongoing
FGFR1-3 AZD4547 NCT01791985 I/II 1 line nsAI failure AZD4547 vs. EXE Ongoing






NCT02115282 III nsAI failure Entinostat + EXE vs. EXE Ongoing
NCT02115594 II HT failure Entinostat + FUL vs. FUL Ongoing
Vorinostat [34] II HT failure Vorinostat + TAM 40 %





NCT01857193 I/II First line LEE011 + everolimus + EXE vs. LEE011 +











NCT02088684 I/II HT failure no more
than 2 lines of CT
BKM120 + LEE001 + FUL vs. BYL719 +
LEE001 + FUL vs. LEE001 + FUL
Ongoing
Abbreviations; CDK: cyclin-dependent kinase, LET: letrozole, FUL: fulvestrant, HT: hormonal therapy, EXE: exemestane, AI: aromatase inhibitor, nsAI: non-steroidal AI, FGFR: fibroblast growth factor receptor, TK: tyrosine
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with breast cancer (MONARCH 3: NCT02246621). Re-
sults from a previous phase I trial demonstrated that
more than 75 % of patients with HR+ breast cancer ex-
perienced either partial response or stable disease after
a second-line treatment with abemaciclib [59].
Preclinical studies had shown that increased expres-
sion of cyclin D1 and pRb were associated with re-
sponse in vitro, as was decreased expression of p16
(a natural CDK4/6 inhibitor) [57]. Unfortunately, in the
phase II PALOMA-1/TRIO-18, patient selection on the
basis of cyclin D1 amplification or p16 loss was not as-
sociated with an improved outcome from palbociclib
treatment [58].
A combinatorial drug screen preclinical study has re-
cently identified that CDK 4/6 inhibition sensitizes cells
with acquired and intrinsic resistance to PI3K inhibition
on multiple PIK3CA mutant cancers with decreased sen-
sitivity to PI3K inhibitors. In fact, the combination of
CDK 4/6 and PI3K inhibitors exhibited synergistic activ-
ity against PIK3CA mutant breast cancer cell lines. The
reason behind this is the fact that cancers resistant to
PI3K inhibitors present with persistence to cyclin D1
pathway activation as determined by the presence of Rb
phosphorylation. In vivo, the combination of PI3K and
CDK 4/6 inhibitors leads to tumor regression in PIK3CA
mutant xenografts, overcoming intrinsic and adaptive re-
sistance to PI3K inhibition [60].
Based on these findings, several phase I/II studies are
currently ongoing with the combination of LEE011 with
fulvestrant and BYL719 or BKM120 (NCT02088684), as
well as LEE011, BYL719, and letrozole (NCT01872260)
in postmenopausal advanced HR+ breast cancer.
FGFR inhibitor
Fibroblast growth factor receptors (FGFRs) are a family
of transmembrane tyrosine kinase receptors belonging
to the fibroblast growth factor (FGF) pathway, that upon
activation promote cell proliferation, migration, angio-
genesis, and survival in cancer cells by the activation of
the Ras-dependent MAPK signaling pathway and PI3K/
Akt/mTOR. FGFR1 amplification has been identified in
around 10 % of HR+ breast cancers, and it has been as-
sociated with a worse prognosis, higher Ki67 expression,
and resistance to endocrine therapy [61, 62]. Several
other less frequent alterations in the FGF pathway have
been identified including FGFR2 amplifications, FGFR3
translocations, and amplifications of different ligands
like FGF3 and FGF4 that might potentially activate the
pathway [41]. Several FGFR inhibitors are currently be-
ing investigated in HR+ advanced breast cancer in order
to reverse resistance to endocrine therapy (Table 2).
Dovitinib (TKI258) is a first-generation oral tyrosine kin-
ase inhibitor (TKI) which inhibits FGFR1-3, VEGFR, andPDGFR. Preclinical data showed that dovitinib inhibits
proliferation in FGFR1- and FGFR2- amplified, but not
in FGFR-normal breast cancer cell lines [63]. Treatment
with dovitinib as monotherapy was evaluated in a phase
II clinical trial in women presenting with advanced HR+
breast cancer [63]. Patients were stratified based on the
presence of FGFR1 amplification and/or FGF pathway
activation determined by qPCR assay. Overall, uncon-
firmed response or stable disease for more than 6 months
was observed in 5 (25 %) and 1 (3 %) patient(s) with
FGFR1-amplified and FGFR1-nonamplified breast can-
cers, respectively. Interestingly, the response rate was
21 % in patients with activated FGF-pathway breast cancer
based on qPCR, compared with a 12 % increase in target
lesions in patients who did not present with FGF pathway
amplification [63]. Dovitinib is currently being investi-
gated in a randomized, placebo-controlled phase II study
in combination with fulvestrant (NCT01528345). Another
agent, AZD4547, specifically inhibits FGFR1 to 3 and is
currently being investigated in ongoing phase I/II trials in
patients with advanced HR+ breast cancer after exposure
to non-steroidal aromatase inhibitors (NCT01791985),
initially in combination with exemestane and posteriorly,
after the results of the BOLERO-2 study, with fulvestrant.
Both studies include patients with and without alterations
in the FGF pathway to determine if there is a role for
FGFR inhibition in endocrine-resistant breast cancer and
if potential benefit is limited to the presence of a deter-
minate molecular aberration.
HDAC inhibitor
Numerous epigenetic mechanisms have increasingly be-
ing revealed and relate to regulation of gene expression
without changing DNA sequence. One of these mecha-
nisms is modification of histone structure by acetylation
which contributes to the dilatation of nucleosomal struc-
ture and the gathering of transcript factors followed by
induction of transcription. The key enzymes, the histone
deacetylases (HDACs), remove acetylation to stop the
transcription, playing an important role in regulating
gene expression [64, 65]. As alterations in HDACs are
found in many human cancers [66–68], histone deacety-
lase inhibitors (HDACi) have aroused interest as a poten-
tial treatment for cancer. The first of these new HDACi,
vorinostat (suberoylanilide hydroxamic acid), has received
FDA approval as monotherapy for treating patients with
cutaneous T-cell lymphoma. Moreover, HDAC inhibition
has proven to be synergistic or additive with different anti-
cancer agents, including radiation therapy [66], chemo-
therapy, and new targeted agents [66, 68–70]. In the case
of breast cancer, the epigenetic silencing of ER target
genes is crucial to ER-independent growth and has been
described as a mechanism of endocrine resistance [71].
Based on that, different HDAC inhibitors are being
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mors resistant to endocrine therapy (Table 2). Vorinostat
has been assessed in combination with tamoxifen in a
non-randomized phase II study in patients previously
treated with endocrine therapy [72]. The overall response
rate was 19 %, and the clinical benefit rate (defined as
stable disease > 24 weeks) was 40 %. Similarly, the results
from the randomized double-blind phase II study of exe-
mestane with or without entinostat, a benzamide HDAC
inhibitor, enrolled 130 patients with resistance to non-
steroidal AI. The PFS was 4.3 versus 2.3 months (HR =
0.73, 95 % CI: 0.50-1.07, P = 0.055), and the OS was 28.1
versus 19.8 months (HR = 0.59, 95 % CI: 0.36-0.97) for the
combination versus the exemestane alone arm, respect-
ively [73]. There is currently ongoing a phase III trial with
the same treatment design for the same population
(NCT02115282), as well as a randomized phase II study of
fulvestrant with or without entinostat (NCT02115594), a
phase II trial of vorinostat in combination with AI treat-
ment (NCT00616967), and a phase I trial of abexinostat
(S78454/PCI-24781), an oral pan-HDAC inhibitor in com-
bination with tamoxifen. The most important dose-
limiting toxicity of these compounds is thrombocytopenia,
which is constantly observed and might limit drug combi-
nations [74].
Targeting ESR1 mutation
Several reports have recently described the appearance
of somatic ESR1 mutations as a potential mechanism of
secondary endocrine resistance in HR+ breast cancer.
Robinson et al. [75, 76] identified ESR1 mutations in 6
of 11 (55 %) HR+ advanced breast tumors. Further,
Toy et al. [66] identified somatic ESR1 mutations in 9 of
36 (25 %) and in 5 of 44 (11%) ER+ metastatic breast
cancers obtained from participants in the BOLERO-2
clinical trial whose disease had progressed during treat-
ment with aromatase inhibitors [34]. A more recent re-
port from Jeselsohn et al. [77] found that, overall, the
frequency of these mutations was 12% (9/76; 95 % CI, 6
% to 21 %) in metastatic tumors, although it increased
up to 20 % (5/25; 95 % CI, 7 % to 41 %) in a subgroup of
patients who received an average of 7 lines of treatment.
Interestingly, sequencing of ER-positive primary tumors
did not identify ESR1 mutations, including some primary
tumors obtained before therapy from a subset of cases
with known ESR1 mutation at metastases [25, 76, 77].
Only Toy et al. identified ESR1 mutations in only 3 % of
183 pretreatment tumor biopsies from BOLERO-2 trial
participants [76]. Moreover, none of these groups identi-
fied any ESR1 mutations when sequencing ER-negative
breast tumors [75–77]. All these results suggest that
ESR1 mutations are rare in newly diagnosed, untreated
breast cancers but appear to be frequently acquired dur-
ing progression to hormone resistance, especially in thecontext of estrogen deprivation therapy. To support
this theory, these mutations seem also to affect the
ligand-binding domain (LBD), encoding p.Tyr537Ser
and p.Asp538Gly, which strongly promote classical ER
signaling of target genes in the absence of ligand, resulting
in the synthesis of receptors with ligand-independent ac-
tivity and could promote resistance to AI treatment. Both
Toy et al. [76] and Robinson et al. [75] showed that mu-
tant ERα protein can still bind antiestrogens such as tam-
oxifen and fulvestrant, although higher doses of these
drugs were required to inhibit this mutant ERα. This
raises the possibility that altered dosing or the develop-
ment of more potent and/or selective ER antagonists
might inhibit residual ER activity and thus overcome re-
sistance in the presence of a mutated ERα.
Yu et al. [78] recently reported that targeting heat
shock protein (HSP) 90, which is the chaperone protein
of ER, may be useful to treat Y537S ESR1-mutated tu-
mors. The authors showed that mutant ESR1 tumors are
highly dependent on HSP90, and preclinical studies with
the HSP90 inhibitor STA9090 demonstrated cytotoxicity
alone and in combination with raloxifene and fulvestrant
to ex vivo cultured circulating breast tumor cells [78].
Interestingly, they also described that the allele frequency
of ESR1 mutation correlated with the sensitivity to HSP90
inhibition. These findings suggest that ESR1-mutation
targeted therapy will be possibly oriented by genomic
portraits from each patient and that there is a need for
more potent or specific antagonists of the mutant forms
to block ER signaling as next-generation selective ER
modulators (SERMs) and selective ER down-regulators
(SERDs).
Conclusion
The mechanism of resistance to endocrine therapy in
patients with ER-positive breast cancer remains a major
issue. Previous studies had already identified a cross-talk
between the ER pathway and growth factors pathways,
mostly PI3K/Akt/mTOR and RAS/RAF/MAPK, as a
main potential mechanism responsible for endocrine re-
sistance. Moreover, the use of high-throughput technolo-
gies has identified several molecular aberrations present in
breast tumors including PIK3CA mutations, AKT, FGFR1,
and CCDN1 amplifications, as well as PTEN loss that con-
tribute to the activation of these pathways and therefore
might propitiate endocrine resistance via non-classical acti-
vation of ER. These findings have been made in parallel to
the development of targeted therapies against these driver
genes, leading to the approval of two new targeted therap-
ies: everolimus and palbociclib against mTOR and CDK4/
6, respectively, in combination with hormonotherapy to
circumvent endocrine resistance. More recently, the dis-
covery of somatic ESR1 mutations in tumors previously
treated with endocrine therapy has directed attention to a
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This, in addition to the results of currently ongoing clinical
trials including combinations of different targeted therapies
and a more comprehensive knowledge of the main mo-
lecular aberrations, will revolutionize the future manage-
ment of ER-positive breast cancer.
Many challenges still remain though, as we try to iden-
tify the subsets of patients most likely to benefit from
these novel targeted agents. A strategy for biological
markers-driven selection of target agents for each patient
and an integrated form for detecting reproducible key mo-
lecular alterations which cause endocrine resistance are
mandatory for future precision medicine in this subset of
breast cancer.
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